FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.

Subsidie
€ 2.494.504
2023

Projectdetails

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic.

Approach

Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed.

Drug Development

Peptomycs first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients.

Biomarker Identification

Moreover, using AI, we identified predictive and pharmacodynamic circulating biomarker signatures, and generated companion diagnostic tests for stratification and real-time response monitoring for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications.

Future Goals

The next steps and goals of this MYCureX project consist of:

  1. Conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity.
  2. Refining the companion diagnostic prototypes and app.
  3. Securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process.
  4. Expanding the applications of OMO-103 and Peptomyc's drug pipeline.

Conclusion

By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.494.504
Totale projectbegroting€ 3.563.578

Tijdlijn

Startdatum1-7-2023
Einddatum31-12-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • PEPTOMYC SLpenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)

iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment.

€ 2.500.000
EIC Accelerator

Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering

The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.

€ 2.434.790
EIC Accelerator

A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.

€ 2.462.533
EIC Accelerator

Multi-omic data driven drug discovery and indication prioritisation platform in oncology

mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.

€ 2.495.788
EIC Accelerator

The ProM platform: New ways to drug the undruggable

PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.

€ 2.461.375

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

Maximizing the use of a first clinically viable MYC inhibitor

This project aims to enhance the therapeutic potential of the MYC inhibitor Omomyc by exploring its delivery methods and combination therapies for treating brain tumors and understanding MYC biology.

€ 2.499.904
Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

€ 20.000
ERC Proof of...

Actionable metabolite supplements to improve treatment response in pancreatic cancer

The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.

€ 150.000
ERC Consolid...

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma

PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.

€ 1.999.401
ERC Proof of...

Curing ovarian cancer through autoantibody-based therapy

This project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials.

€ 150.000